Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytosine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Cytosine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-002267-25 Sponsor Protocol Number: SEOTP-2018 Start Date*: 2018-07-18
    Sponsor Name:Fakultní nemocnice Brno
    Full Title: SAFETY AND EFFICACY OF OLANZAPINE TREATMENT IN PSYCHOSIS: EFFECT OF GENETIC AND EPIGENETIC FACTORS – COVARIATES OF TREATMENT RESPONSE
    Medical condition: Psychoses
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010114-30 Sponsor Protocol Number: D1531C00009 Start Date*: 2009-06-23
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) i...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004956-60 Sponsor Protocol Number: UCL/08/0121 Start Date*: 2009-08-14
    Sponsor Name:University College London
    Full Title: Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma
    Medical condition: Refractory Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004661-15 Sponsor Protocol Number: CLI-037 Start Date*: 2005-05-17
    Sponsor Name:Vion Pharmaceuticals, Inc.
    Full Title: A Phase III Randomized Study of CLORETAZINE™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse
    Medical condition: Acute Myeloid Leukemia (AML) in First Relapse
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2008-008518-38 Sponsor Protocol Number: CP4055-205 Start Date*: 2009-09-30
    Sponsor Name:Clavis Pharma ASA
    Full Title: A Phase II Study of Elacytarabine plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia
    Medical condition: Acute Myeloid Leukaemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005052-37 Sponsor Protocol Number: BRAVO Start Date*: 2021-04-01
    Sponsor Name:Institute of Mother and Child
    Full Title: Optymalizacja czasu leczenia i dawkowania wemurafenibu u małoletnich pacjentów z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych z obecnością mutacji w genie BRAF.
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005053-25 Sponsor Protocol Number: TRAM Start Date*: Information not available in EudraCT
    Sponsor Name:Institute of Mother and Child
    Full Title: Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment.
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004912-28 Sponsor Protocol Number: EORTC06061 Start Date*: 2012-02-17
    Sponsor Name:European Organisation for Research and Treatment on Cancer
    Full Title: Clofarabine in combination with a standard remission induction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukem...
    Medical condition: Previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007553-31 Sponsor Protocol Number: AMLSG10-07 Start Date*: Information not available in EudraCT
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Phase I/II Clinical Study of SU11248 (Sutent) combined with Standard Chemotherapy with Cytosine Arabinoside and Daunorubicin in Patients with FLT3 mutated AML over 60 years of age
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023271-26 Sponsor Protocol Number: MI-CI-C02 Start Date*: 2011-02-01
    Sponsor Name:Mithra Pharmaceuticals SA
    Full Title: A randomized, double-blind, multi-centre, placebo controlled phase II clinical study to evaluate the efficacy, tolerance and safety of an aqueous gel containing 2% (w/w) of cidofovir, directly appl...
    Medical condition: High Grade of Cervical Intraepithelial Neoplasia (CIN).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007494 Carcinoma uterine cervix in situ LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003293-25 Sponsor Protocol Number: DIM05 Start Date*: 2007-11-20
    Sponsor Name:Medivation, Inc.
    Full Title: A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003103-12 Sponsor Protocol Number: AML-CG2008 Start Date*: 2009-03-10
    Sponsor Name:Hospital of the University of Munich
    Full Title: A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy ...
    Medical condition: Adult patients (≥18 years) with newly-diagnosed acute myeloid leukemia (AML) - except acute promyelocytic leukemia (APL) and t(15;17)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003353-16 Sponsor Protocol Number: GS-US-339-1559 Start Date*: 2017-04-18
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML)
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001628-72 Sponsor Protocol Number: P001317 Start Date*: 2017-07-18
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
    Medical condition: Primary central nervous system lymphoma (PCNSL) is an aggressive Non-Hodgkin Lymphoma (NHL) mostly of B-cell origin, which exclusively invades the central nervous system compartment. It accounts fo...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001789-41 Sponsor Protocol Number: ET18000120 Start Date*: 2019-07-16
    Sponsor Name:Centre Léon Bérard
    Full Title: Trial Of Imatinib After Ponatinib Induction (Tipi) - A multicentre, open label phase II trial evaluating the safety and efficacy of ponatinib induction followed by imatinib maintenance in adult pat...
    Medical condition: Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), all risk scores, ≤65 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001181-10 Sponsor Protocol Number: P003077 Start Date*: 2023-04-13
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand...
    Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003453-28 Sponsor Protocol Number: SOMCT03 Start Date*: 2022-03-28
    Sponsor Name:SOM Innovation Biotech SA (SOM Biotech)
    Full Title: Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with chore...
    Medical condition: Huntington’s Disease with choreic movements.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) IT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014445-80 Sponsor Protocol Number: CP4055-306 Start Date*: 2010-06-23
    Sponsor Name:Clavis Pharma
    Full Title: A Randomised Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukaemia
    Medical condition: Late Stage Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066764 Acute myeloid leukaemia progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed) ES (Ongoing) BE (Completed) PL (Completed) IT (Ongoing) GB (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001888-23 Sponsor Protocol Number: TV7820-CNS-20002 Start Date*: 2014-03-25
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus...
    Medical condition: Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed) AT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000868-83 Sponsor Protocol Number: CP4055-106 Start Date*: 2008-04-30
    Sponsor Name:Clavis Pharma ASA
    Full Title: A Phase I/II Study of CP-4055 in Patients with Refractory/Relapsed Hematologic Malignancies
    Medical condition: Phase II. Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 08:38:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA